In 1949, the same year India adopted its constitution, a group of businessmen and medical professionals in Mumbai founded The Indian Pharmaceutical Combine Association. Seventy-five years later, that company — now called IPCA Laboratories — is one of the world’s largest manufacturers of antimalarial drugs, supplying hydroxychloroquine and chloroquine to malaria-endemic countries across Africa, Asia, and Latin America. Along the way, IPCA grew from a single API factory into a fully integrated pharmaceutical enterprise with 18 manufacturing units, over 350 formulations, and exports to more than 100 countries.
IPCA’s longevity is not merely a biographical detail — it is a competitive advantage. The company was manufacturing APIs in India before most of its competitors were incorporated. That early start meant IPCA built deep expertise in process chemistry for molecules like atenolol, chloroquine phosphate, and hydroxychloroquine sulphate at a time when few Indian companies had the technical capacity to produce them. IPCA was the first manufacturer in India for all three of these APIs, and it remains one of the world’s largest suppliers of each.
The business model is vertically integrated in the truest sense: IPCA makes its own APIs, formulates them into tablets, capsules, and oral liquids, and markets the finished products under its own brands in India and in more than 36 countries directly. The API division accounts for roughly 20% of total revenue, with nearly 80% of API production going to export markets — serving multinational pharmaceutical firms that rely on IPCA for bulk supply of proven molecules. The formulations division contributes the remaining 80%, split between domestic branded generics and international branded and generic sales.
This integration gives IPCA a cost structure that is difficult to match. When you make the active ingredient, formulate the finished product, and distribute it under your own brand, the margins that would normally be distributed across three or four companies along the value chain are captured by one. It is the same logic that made Henry Ford build River Rouge — except applied to antimalarials and cardiovascular drugs.
IPCA’s relationship with antimalarial drugs is as old as the company itself. Chloroquine and hydroxychloroquine were among its earliest API products, and the company has been a principal supplier of these molecules to global health agencies and national malaria control programmes for decades. Its antimalarial portfolio includes chloroquine phosphate, hydroxychloroquine sulphate (marketed under the HCQS brand), artemether-lumefantrine combinations (Lumerax), and pyrimethamine-sulfadoxine (Laridox) for chloroquine-resistant falciparum malaria.
When the global demand for hydroxychloroquine spiked in early 2020, IPCA was one of the few companies in the world with the installed capacity to respond at scale. The company’s role as a critical supplier of antimalarials to developing nations is not a corporate social responsibility initiative — it is the core of the business. IPCA makes antimalarials because it has been making them since the 1950s, and the process knowledge, regulatory approvals, and supply-chain relationships it has accumulated over seven decades are not easily replicated.
Beyond antimalarials, IPCA has built strong franchises in pain management (the Zerodol brand of aceclofenac, which ranks among India’s top 300 pharmaceutical brands), rheumatology, cardiovascular (including atenolol and amlodipine formulations), anti-diabetics, and gastrointestinal therapies. The domestic business contributed roughly 48% of FY 2025 revenue, with the field force covering a broad prescriber base across therapeutic areas.
IPCA’s international presence is broader than most Indian pharmaceutical companies of its size. The company exports formulations and APIs to more than 100 countries, with direct branded operations in over 36 markets across Asia, Africa, the CIS nations, and Latin America. In regulated markets like the United Kingdom and Canada, IPCA supplies generic formulations and APIs under its own registrations. In Africa, it is a significant supplier of antimalarials and essential medicines to both public-sector procurement agencies and private pharmacy chains.
The manufacturing backbone behind this reach is substantial: 18 manufacturing units across India, approved by the US FDA, UK MHRA, South Africa’s MCC, Brazil’s ANVISA, and Australia’s TGA. IPCA also operates a US subsidiary, Pisgah Laboratories, which provides additional capacity and a local presence for its American business. The regulatory portfolio gives IPCA the ability to sell in virtually every major pharmaceutical market in the world, a capability that took decades of plant audits, filings, and remediation cycles to build.
IPCA’s revenue is balanced between its domestic branded business and its international operations. India contributes approximately 48% of revenue through branded generics sold to hospitals and retail pharmacies. Exports — split between branded generics in emerging markets, generic sales in regulated markets, and bulk API shipments — account for the remaining 52%, making IPCA one of India’s top API exporters by volume.
IPCA’s 18 manufacturing units represent one of the most diversified pharmaceutical production footprints in India. The facilities span API synthesis, formulation manufacturing (tablets, capsules, oral liquids, dry powders), and packaging — all within India. Multiple plants carry US FDA approval, and the company maintains active registrations with the UK MHRA, ANVISA, TGA, and other regulatory authorities across Europe, Africa, and Asia.
The company has navigated regulatory challenges, including FDA import alerts that temporarily restricted certain product shipments to the US market. IPCA responded with plant remediation programmes, upgraded quality systems, and reinspection campaigns — a pattern common among Indian pharmaceutical companies that have invested in bringing legacy plants up to evolving global standards. IPCA holds 33 US FDA drug approvals (all ANDAs) and 37 Indian Patent Office grants, reflecting process innovations across its API and formulation capabilities.
Sources: IPCA Laboratories Annual Reports FY2019–20 through FY2024–25. US FDA facility registration and inspection records. UK MHRA GMP certificates. Indian patent office records. Company investor presentations.